Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 04 2022
12 04 2022
Historique:
received:
08
04
2021
accepted:
17
03
2022
entrez:
13
4
2022
pubmed:
14
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitumor immunity. Understanding of the mechanisms of arthritis-irAE is critical to overcome this challenge, but the pathophysiology remains unknown. Here, we comprehensively analyze peripheral blood and/or synovial fluid samples from 20 patients with arthritis-irAE, and unmask a prominent Th1-CD8
Identifiants
pubmed: 35413951
doi: 10.1038/s41467-022-29539-3
pii: 10.1038/s41467-022-29539-3
pmc: PMC9005525
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1970Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI163412
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141966
Pays : United States
Organisme : NIH HHS
ID : S10 OD024977
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221703
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL143520
Pays : United States
Organisme : NIAMS NIH HHS
ID : K08 AR079587
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Suarez-Almazor, M. E., Kim, S. T., Abdel-Wahab, N. & Diab, A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 69, 687–699 (2017).
pubmed: 28085999
doi: 10.1002/art.40043
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377–2385 (2017).
pubmed: 28945858
doi: 10.1093/annonc/mdx286
Calabrese, L. H., Calabrese, C. & Cappelli, L. C. Rheumatic immune-related adverse events from cancer immunotherapy. Nat. Rev. Rheumatol. 14, 569–579 (2018).
pubmed: 30171203
doi: 10.1038/s41584-018-0074-9
Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).
pubmed: 27141885
doi: 10.1038/nrclinonc.2016.58
Subedi, A., Strauss, J. & Gupta, S. Erosive deforming inflammatory arthritis in a patient with cervical adenocarcinoma. JAMA Oncol. 5,1628–1629 (2019).
Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).
pubmed: 29162153
pmcid: 5697162
doi: 10.1186/s40425-017-0300-z
Faje, A. T. et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706–3714 (2018).
pubmed: 29975414
doi: 10.1002/cncr.31629
Scott, S. C. & Pennell, N. A. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J. Thorac. Oncol. 13, 1771–1775 (2018).
pubmed: 29935305
doi: 10.1016/j.jtho.2018.06.004
Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275–4280 (2010).
pubmed: 20160101
pmcid: 2840093
doi: 10.1073/pnas.0915174107
Altman, R. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29, 1039–1049 (1986).
pubmed: 3741515
doi: 10.1002/art.1780290816
Pundole, X., Abdel-Wahab, N. & Suarez-Almazor, M. E. Arthritis risk with immune checkpoint inhibitor therapy for cancer. Curr. Opin. Rheumatol. 31, 293–299 (2019).
pubmed: 30870217
doi: 10.1097/BOR.0000000000000601
Cappelli, L. C. et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 48, 553–557 (2018).
pubmed: 29573850
pmcid: 6150859
doi: 10.1016/j.semarthrit.2018.02.011
Leipe, J. et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 4, e000714 (2018).
pubmed: 30167328
pmcid: 6109812
doi: 10.1136/rmdopen-2018-000714
Buder-Bakhaya, K. et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol. Immunother. 67, 175–182 (2018).
pubmed: 29018908
doi: 10.1007/s00262-017-2069-9
Anderson, J. et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64, 640–647 (2012).
doi: 10.1002/acr.21649
Kim, S. T. et al. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. J. Immunother. Cancer 7, 126 (2019).
pubmed: 31088575
pmcid: 6518723
doi: 10.1186/s40425-019-0597-x
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).
pubmed: 25860605
pmcid: 5905674
doi: 10.1016/j.cell.2015.03.030
Craft, J. E. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol. 8, 337–347 (2012).
pubmed: 22549246
pmcid: 3604997
doi: 10.1038/nrrheum.2012.58
Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665–673 (2018).
pubmed: 29925983
pmcid: 7882196
doi: 10.1038/s41590-018-0120-4
Cretney, E., Kallies, A. & Nutt, S. L. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol. 34, 74–80 (2013).
pubmed: 23219401
doi: 10.1016/j.it.2012.11.002
Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130, 3137–3150 (2020).
pubmed: 32125291
pmcid: 7260038
doi: 10.1172/JCI130426
Lucca, L. E. et al. TIGIT signaling restores suppressor function of Th1 Tregs. JCI insight 4, e124427 (2019).
Bauche, D. et al. LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. Immunity 49, 342–352 e345 (2018).
pubmed: 30097293
doi: 10.1016/j.immuni.2018.07.007
Wei, X. et al. Reciprocal Expression of IL-35 and IL-10 defines two distinct effector treg subsets that are required for maintenance of immune tolerance. Cell Rep. 21, 1853–1869 (2017).
pubmed: 29141218
doi: 10.1016/j.celrep.2017.10.090
Koizumi, S. I. et al. JunB regulates homeostasis and suppressive functions of effector regulatory T cells. Nat. Commun. 9, 5344 (2018).
pubmed: 30559442
pmcid: 6297218
doi: 10.1038/s41467-018-07735-4
Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346–1358 (2020).
pubmed: 32868929
doi: 10.1038/s41590-020-0769-3
Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745–763 (2004).
pubmed: 15032595
doi: 10.1146/annurev.immunol.22.012703.104702
Wakim, L. M., Woodward-Davis, A. & Bevan, M. J. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc. Natl Acad. Sci. 107, 17872–17879 (2010).
pubmed: 20923878
pmcid: 2964240
doi: 10.1073/pnas.1010201107
Ely, K. H., Cookenham, T., Roberts, A. D. & Woodland, D. L. Memory T cell populations in the lung airways are maintained by continual recruitment. J. Immunol. 176, 537–543 (2006).
pubmed: 16365448
doi: 10.4049/jimmunol.176.1.537
Gebhardt, T. et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 477, 216–219 (2011).
pubmed: 21841802
doi: 10.1038/nature10339
Elemam, N. M., Hannawi, S. & Maghazachi, A. A. Role of chemokines and chemokine receptors in rheumatoid arthritis. Immunotargets Ther. 9, 43–56 (2020).
pubmed: 32211348
pmcid: 7074856
doi: 10.2147/ITT.S243636
Kim, S. T. et al. Human extrafollicular CD4(+) Th cells help memory B cells produce Igs. J. Immunol. 201, 1359–1372 (2018).
pubmed: 30030323
doi: 10.4049/jimmunol.1701217
Wei, S. C. et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell 170, 1120–1133 e1117 (2017).
pubmed: 28803728
pmcid: 5591072
doi: 10.1016/j.cell.2017.07.024
Braaten, T. J. et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann. Rheum. Dis. 79, 332–338 (2019).
Aggarwal, B. B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745–756 (2003).
pubmed: 12949498
doi: 10.1038/nri1184
Kishimoto, T., Kang, S. & Tanaka, T. IL-6: A New Era for the treatment of autoimmune inflammatory diseases. in Innovative Medicine: Basic Research and Development (eds. Nakao, K., Minato, N. & Uemoto, S.) 131–147 (Tokyo, 2015).
Martinez, G. J., Nurieva, R. I., Yang, X. O. & Dong, C. Regulation and function of proinflammatory TH17 cells. Ann. N. Y Acad. Sci. 1143, 188–211 (2008).
pubmed: 19076351
pmcid: 5793850
doi: 10.1196/annals.1443.021
Naing, A. et al. Strategies for improving the management of immune-related adverse events. J. Immunother. Cancer 8, e001754 (2020).
Tang, M., Tian, L., Luo, G. & Yu, X. Interferon-gamma-mediated osteoimmunology. Front. Immunol. 9, 1508 (2018).
pubmed: 30008722
pmcid: 6033972
doi: 10.3389/fimmu.2018.01508
Chemin, K., Gerstner, C. & Malmstrom, V. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front. Immunol. 10, 353 (2019).
pubmed: 30915067
pmcid: 6422991
doi: 10.3389/fimmu.2019.00353
Chu, C. Q., Swart, D., Alcorn, D., Tocker, J. & Elkon, K. B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 56, 1145–1151 (2007).
pubmed: 17393396
doi: 10.1002/art.22453
Boissier, M. C. et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur. J. Immunol. 25, 1184–1190 (1995).
pubmed: 7774621
doi: 10.1002/eji.1830250508
Sarkar, S. et al. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther. 11, R158 (2009).
pubmed: 19852819
pmcid: 2787258
doi: 10.1186/ar2838
Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928–942 (2019).
pubmed: 31061532
pmcid: 6602051
doi: 10.1038/s41590-019-0378-1
Lee, E. J. et al. Bulk and single cell transcriptomic data indicate that a dichotomy between inflammatory pathways in peripheral blood and arthritic joints complicates biomarker discovery. Cytokine 127, 154960 (2020).
pubmed: 31881419
doi: 10.1016/j.cyto.2019.154960
van Amelsfort, J. M., Jacobs, K. M., Bijlsma, J. W., Lafeber, F. P. & Taams, L. S. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50, 2775–2785 (2004).
pubmed: 15457445
doi: 10.1002/art.20499
Di Giovangiulio, M. et al. Tbet expression in regulatory T cells is required to initiate Th1-mediated colitis. Front. Immunol. 10, 2158 (2019).
pubmed: 31572375
pmcid: 6749075
doi: 10.3389/fimmu.2019.02158
Kim, B.-S. et al. Generation of RORγt+ antigen-specific T regulatory 17 cells from Foxp3+ precursors in autoimmunity. Cell Rep. 21, 195–207 (2017).
pubmed: 28978473
pmcid: 5716359
doi: 10.1016/j.celrep.2017.09.021
de Kleer, I. M. et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172, 6435–6443 (2004).
pubmed: 15128835
doi: 10.4049/jimmunol.172.10.6435
Kim, K. H. et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 9, 1722023 (2020).
pubmed: 32076579
pmcid: 6999841
doi: 10.1080/2162402X.2020.1722023
Wallin, J. J. et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
pubmed: 27571927
pmcid: 5013615
doi: 10.1038/ncomms12624
Yan, Y. et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI insight 3, e97828 (2018).
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
pubmed: 27806233
pmcid: 5247797
doi: 10.1056/NEJMoa1609214
Laubli, H. et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology 7, e1386362 (2018).
pubmed: 29308309
doi: 10.1080/2162402X.2017.1386362
Nanki, T. et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2878–2883 (2002).
pubmed: 12428227
doi: 10.1002/art.10622
Yellin, M. et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1730–1739 (2012).
pubmed: 22147649
doi: 10.1002/art.34330
Nanki, T. et al. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 52, 3004–3014 (2005).
pubmed: 16200580
doi: 10.1002/art.21301
Ruth, J. H. et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 54, 765–778 (2006).
pubmed: 16508941
pmcid: 1472704
doi: 10.1002/art.21662
Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207–215 (2011).
pubmed: 21221121
doi: 10.1038/icb.2010.158
Mossanen, J. C. et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4(+) T-cell-dependent control of senescence. Gastroenterology 156, 1877–1889 e1874 (2019).
pubmed: 30710528
doi: 10.1053/j.gastro.2019.01.247
McKinley, L. et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181, 4089–4097 (2008).
pubmed: 18768865
doi: 10.4049/jimmunol.181.6.4089
Ramesh, R. et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211, 89–104 (2014).
pubmed: 24395888
pmcid: 3892977
doi: 10.1084/jem.20130301
Ying, H. et al. Cutting edge: CTLA-4–B7 interaction suppresses Th17 cell differentiation. J. Immunol. 185, 1375–1378 (2010).
pubmed: 20601598
doi: 10.4049/jimmunol.0903369
von Euw, E. et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35 (2009).
doi: 10.1186/1479-5876-7-35
Kotake, S., Yago, T., Kobashigawa, T. & Nanke, Y. The Plasticity of Th17 cells in the pathogenesis of rheumatoid arthritis. J. Clin. Med. 6, 67 (2017).
Maggi, L. et al. Th17 and Th1 Lymphocytes in Oligoarticular Juvenile Idiopathic Arthritis. Front. Immunol. 10, 450 (2019).
pubmed: 30930898
pmcid: 6428030
doi: 10.3389/fimmu.2019.00450
Basdeo, S. A. et al. Ex-Th17 (Nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells. J. Immunol. 198, 2249–2259 (2017).
pubmed: 28167631
doi: 10.4049/jimmunol.1600737
Murray-Brown, W. et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J. Immunother. Cancer 8, e000281 (2020).
Penkava, F. et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat. Commun. 11, 4767 (2020).
pubmed: 32958743
pmcid: 7505844
doi: 10.1038/s41467-020-18513-6
Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655–671 e622 (2020).
pubmed: 32603654
pmcid: 7415717
doi: 10.1016/j.cell.2020.06.001
Osa, A. et al. Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients. JCI insight 3, e59125 (2018).
Ilicic, T. et al. Classification of low quality cells from single-cell RNA-seq data. Genome Biol. 17, 1–15 (2016).
doi: 10.1186/s13059-016-0888-1
Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).
pubmed: 34663807
pmcid: 8524723
doi: 10.1038/s41467-021-26282-z
Wang, R. et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat. Med. 27, 141–151 (2021).
pubmed: 33398161
pmcid: 8074162
doi: 10.1038/s41591-020-1125-8
Sinjab, A. et al. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov. 11, 2506–2523 (2021).
Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281–291 e289 (2019).
pubmed: 30954476
pmcid: 6625319
doi: 10.1016/j.cels.2018.11.005
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819
pmcid: 6884693
doi: 10.1038/s41592-019-0619-0
Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888–1902 e1821 (2019).
pubmed: 31178118
pmcid: 6687398
doi: 10.1016/j.cell.2019.05.031
McInnes, L., Healy, J. & Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:1802.03426 (2018).
Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018).
pubmed: 29988129
doi: 10.1038/s41591-018-0096-5
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 e1020 (2018).
pubmed: 30388456
pmcid: 6641984
doi: 10.1016/j.cell.2018.10.038
Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442–459 e429 (2020).
pubmed: 32302573
doi: 10.1016/j.cell.2020.03.048
Wang, Y. et al. iTALK: an R package to characterize and illustrate intercellular communication. BioRxiv, 507871 (2019).
McMurchy, A. N. & Levings, M. K. Suppression assays with human T regulatory cells: a technical guide. Eur. J. Immunol. 42, 27–34 (2012).
pubmed: 22161814
doi: 10.1002/eji.201141651